Table 5.
Empirical Antimicrobial Therapy in Patients Infected with E. anophelis Isolates
| Isolates No. | Specimen | ESBL+MBLs | Empirical Antimicrobial Therapy | Prognosis |
|---|---|---|---|---|
| NO1 | Blood | CME-1+ BlaB-2+ GOB-20 | Ceftazidime+ Levofloxacin+ Teicoplanin | Survival |
| NO2 | Sputum | CME-1+ BlaB-2+ GOB-20 | Cefoperazone-sulbactam+ Minocycline | Non-survival |
| NO3 | Sputum | CME-1+ BlaB-29+ GOB-38 | Cefoperazone-sulbactam+ Teicoplanin | Non-survival |
| NO4 | Urine | CME-1+ BlaB-29+ GOB-38 | Survival | |
| NO5 | Sputum | CME-1+ BlaB-29+ GOB-38 | Cefoperazone-sulbactam+ Minocycline+ Levofloxacin+ Teicoplanin | Non-survival |
| NO6 | Sputum | CME-1+ BlaB-34+ GOB-32 | Piperacillin-tazobactam+ Imipenem | Non-survival |
| NO7 | Urine | CME-1+ BlaB-29+ GOB-38 | Meropenem | Survival |
| NO8 | Urine | CME-1+ BlaB-29+ GOB-38 | Imipenem+ Cefoperazone-sulbactam | Non-survival |
| NO9 | Sputum | CME-1+ BlaB-29+ GOB-38 | Imipenem+ Clindamycin+ Teicoplanin+ Cefepime | Survival |
| NO10 | Blood | CME-1+ BlaB-29+ GOB-38 | Imipenem+ Gentamicin+ Teicoplanin | Non-survival |
| NO11 | Sputum | CME-1+ BlaB-33+ GOB-4 | Cefazolin | Non-survival |
| NO12 | Urine | CME-1+ BlaB-2+ GOB-50 | Teicoplanin | Non-survival |
| NO13 | Sputum | CME-1+ BlaB-29+ GOB-38 | Piperacillin-tazobactam+ ceftriaxone+ Ornidazole | Survival |
| NO14 | Cerebrospinal fluid | Levofloxacin | Survival | |
| NO15 | Blood | CME-1+ BlaB-3+ GOB-45 | Teicoplanin | Survival |
| NO16 | Sputum | CME-1+ BlaB-9+ GOB-32 | Levofloxacin+ Cefazolin+ Amikacin | Non-survival |
| NO17 | Sputum | CME-1+ BlaB-1+ GOB-32 | Imipenem+ Teicoplanin | Non-survival |
| NO18 | Amniotic fluid | CME-1+ BlaB-1+ GOB-38 | Cefuroxime | Survival |
| NO19 | Blood | Ceftriaxone + Vancomycin | Survival | |
| NO20 | Sputum | CME-1+ BlaB-2+ GOB-20 | Cefazolin | Non-survival |
| NO21 | Sputum | CME-1+ BlaB-2+ GOB-50 | Cefoperazone-sulbactam+ Levofloxacin+ Imipenem+ Teicoplanin | Survival |
| NO22 | Sputum | CME-1+ BlaB-17+ GOB-40 | Amikacin | Survival |
| NO23 | Cerebrospinal fluid | CME-1+ BlaB-17+ GOB-20 | Levofloxacin | Survival |
| NO24 | Conjunctival sac | CME-1+ BlaB-29+ GOB-38 | Cefazolin | Survival |
| NO25 | Sputum | CME-2+ BlaB-2+ GOB-39 | Imipenem+ Teicoplanin+ Ornidazole | Survival |
| NO26 | Peritoneal fluid | CME-1+ BlaB-29+ GOB-38 | Meropenem+ Vancomycin | Non-survival |
| NO27 | Urine | CME-1+ BlaB-29+ GOB-38 | Meropenem+ Vancomycin+ Amikacin+ ceftazidime | Non-survival |
| NO28 | Cerebrospinal fluid | CME-1+ BlaB-29+ GOB-38 | Ceftriaxone | Non-survival |
| NO29 | Sputum | CME-1+ BlaB-29+ GOB-38 | Linezolid+ Imipenem | Survival |
| NO30 | Corneal | CME-1+ BlaB-29+ GOB-38 | Amikacin | Survival |
| NO31 | Blood | CME-1+ BlaB-29+ GOB-38 | Imipenem + Levofloxacin+ Amikacin+ Teicoplanin | Non-survival |
| NO32 | Sputum | BlaB-1+ GOB-20 | Cefoperazone-sulbactam+ Minocycline | Non-survival |
| NO33 | Urine | CME-1+ BlaB-1+ GOB-20 | Cefepime+ Cefoperazone-sulbactam | Non-survival |
| NO34 | Sputum | CME-1+ GOB-38 | Imipenem | Survival |
| NO35 | Sputum | CME-1+ BlaB-29+ GOB-38 | Cefoperazone-sulbactam+ Minocycline | Survival |
| NO36 | Urine | CME-1+ BlaB-17+ GOB-50 | Cefoperazone-sulbactam+ Amikacin+ Metronidazole+ Ceftriaxone |
Non-survival |
| NO37 | Blood | CME-2+ BlaB-1+ GOB-20 | Meropenem+ Cefoperazone-sulbactam+ Piperacillin-tazobactam | Non-survival |
| NO38 | Sputum | CME-1+ BlaB-1+ GOB-20 | Imipenem+ Teicoplanin+ Piperacillin-tazobactam | Non-survival |
| NO39 | Urine | CME-1+ BlaB-29+ GOB-38 | Survival |
Abbreviations: ESBL, extended-spectrum beta-lactamase; MBLs, metallo-beta-lactamases; CME, extended-spectrum serine-beta-lactamase CME (class A); BlaB, metallo-beta-lactamase BlaB (subclass B1); GOB, metallo-beta-lactamase GOB (subclass B3).